Vireo Growth (VREOF) Tax Provisions (2020 - 2026)
Vireo Growth (VREOF) reported Tax Provisions of $18.3 million for Q1 2026, up 976.47% on a YoY basis from $1.7 million in Q1 2025, and down 15.8% sequentially from $21.7 million in Q4 2025.
Vireo Growth (VREOF) Tax Provisions (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Tax Provisions data on file, last reported at $18.3 million in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions rose 976.47% year-over-year to $18.3 million; the trailing twelve-month figure through Mar 2026 stood at $58.2 million (up 556.68% YoY), and the FY2025 full-year result was $41.6 million, up 274.42% from the prior year.
- Tax Provisions fell to $18.3 million in Q1 2026, from $21.7 million in the prior quarter.
- In the past five years, Tax Provisions ranged from a high of $21.7 million in Q4 2025 to a low of -$1.3 million in Q4 2023.
- A 5-year average of $4.9 million and a median of $2.0 million in 2022 frame the typical range for Tax Provisions.
- Across the five-year window, Tax Provisions slumped 167.61% in 2023 and surged 1003.18% in 2025, its largest moves.
- Tracing VREOF's Tax Provisions over 5 years: stood at $2.0 million in 2022, then tumbled by 167.61% to -$1.3 million in 2023, then soared by 428.55% to $4.3 million in 2024, then surged by 400.41% to $21.7 million in 2025, then retreated by 15.8% to $18.3 million in 2026.
- Business Quant data shows VREOF's Tax Provisions at $18.3 million in Q1 2026, $21.7 million in Q4 2025, and $13.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 43.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 18.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.30 Mn |
| Dec 31, 2025 | 21.73 Mn |
| Sep 30, 2025 | 13.35 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | 4.34 Mn |
| Sep 30, 2024 | 2.39 Mn |
| Jun 30, 2024 | 440,000.00 |
| Mar 31, 2024 | 3.95 Mn |
| Dec 31, 2023 | -1.32 Mn |
| Sep 30, 2023 | 3.98 Mn |
| Jun 30, 2023 | 1.65 Mn |
| Mar 31, 2023 | 1.73 Mn |
| Dec 31, 2022 | 1.96 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 965,000.00 |
| Mar 31, 2022 | 1.38 Mn |
| Dec 31, 2021 | 2.31 Mn |
| Sep 30, 2021 | 530,000.00 |
| Jun 30, 2021 | 885,000.00 |